Omeros Corporation
Research Omeros Corporation (OMER) on Bullrun: market cap USD 1.39B, P/E 13.4. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOMER
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.39B
- P/E13.4
- Financial periodQ1 2026
- RevenueUSD 9.89M
- Net incomeUSD 56.06M
- Free cash flow-USD 14.51M
- Gross margin94.1%
Valuation Snapshot
latest market cap is USD 1.39B; P/E is 13.4.
Peer valuation comparison
Latest P/E is 13.41x versus a Healthcare sector median of 24.46x (45.2% below).
Latest P/E is 13.41x versus a United States median of 24.87x (46.1% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 3.35M | -USD 116.16M | n/a | -0.05 | USD 9.66M | USD 87.90M | -USD 121.23M |
| FY2024 | USD 0 | -USD 156.82M | -USD 148.97M | n/a | -2.7 | USD 3.40M | USD 164.90M | -USD 182.61M |
| FY2023 | USD 0 | -USD 117.81M | USD 74.30M | n/a | -1.88 | USD 7.11M | USD 213.16M | -USD 24.98M |
| FY2022 | n/a | USD 47.42M | -USD 86.60M | n/a | 0.76 | USD 11.01M | USD 315.29M | USD 85.68M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.39B | 13.4 | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.23B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 573.48M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 205.57M | 10.2 | n/a | n/a |
| 2022 | 2022-12-30 | USD 141.77M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 402.70M | n/a | n/a | n/a |
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Omeros Corporation's market cap?
Omeros Corporation's market capitalization is USD 1.39B.
What is Omeros Corporation's P/E ratio?
Omeros Corporation's price-to-earnings (P/E) ratio is 13.4.
What does Omeros Corporation do?
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.